|
|
View in
browser | Distributed by Center for Medicaid and CHIP Services
(CMCS)
|
|
|
|
Today, the Centers
for Medicare & Medicaid Services (CMS) issued guidance about newly
required Medicaid coverage for treatment of opioid use disorders.
Medication-assisted treatment (MAT) is an evidence-based treatment that
consists of the administration of medications and related behavioral
therapies. The guidance reflects the Trump Administration’s ongoing
commitment to combatting the nation’s opioid crisis.
The guidance issued
today provides information to state Medicaid programs about a new mandatory
Medicaid benefit added under the Substance Use-Disorder Prevention that
Promotes Opioid Recovery and Treatment for Patients and Communities Act
(SUPPORT Act). Under the new benefit, state Medicaid programs must cover
all drugs and biologicals approved or licensed by the FDA to treat opioid
use disorders, including methadone, along with related counseling services
and behavioral therapies. The guidance provides states with information on
the medications and treatment services included in the new MAT benefit and
the locations where MAT can be provided. The guidance also includes
information on other Medicaid authorities to help states expand their
opioid use disorder service continuum, as well as other opportunities
afforded by the SUPPORT Act.
|
|
Stay connected with Medicaid.gov and CMS:
No comments:
Post a Comment